DEVELOP
Growth innovative SMBs action plan
GD¤co, ¤conomic Development Group
GD€co, the €conomic Development Group, aims to reflect on actions and tools that Lyonbiopole has to implement in order to support SMBs development. The GD€co also makes recommendations which will be implemented after approval by the Board of Directors.
There are 15 people “intuitu personae” involved in the support to company’s development and committed to Lyonbiopole: Cécile Réal, Ariana Pharma - Fabrice Plasson, young entrepreneur in Amoéba - François Miceli, Imaxio - François Roy, Créalys - François Valencony, Mérieux Développement - Gilles Alberici, Orega Biotech - Grégoire Franoux, Flamel Technologies - Hélène Rouquette, IDD-Tech - Karine Lignel, Vizille Capital Innovation - Laurent Buffat, Altrabio - Nadia Kamal, Créalys - Nicolas Pasqual, ImmunID - Sandra Dubos, Oseo - Stéphane Legastelois, Indicia Biotechnology - Thierry Abribat, Alizé Pharma - Tristan Rousselle, PX Therapeutics.
The GD€co meets every 3 to 4 months.
More information
They speak about...
« As part of the COOPOL program, PX’Therapeutics, a service company specialized in engineering and production of recombinant proteins for biomedical research, assessed the advantages of setting up a facility in China. In June, I will be meeting local university and industrial organizations to discuss the potential for R&D or trade cooperation focusing on the development of biological candidates. »
Nicolas Mouz
PX’Therapeutics - Scientific Director and co-founder